BridgeBio Oncology Therapeutics, Inc. BBOT 深 滬
等待開盤 01-29 09:30:00 美东时间
12.98
-0.630
-4.63%
華盛通- 最 高13.7141
- 今 開13.67
- 成交量 15.97万股
- 最 低 12.925
- 昨 收 13.61
- 總市值 10.38亿
- 52周最高 14.87
- 市盈率 靜 40.15
- 換手率 0.20%
- 52周最低 8.50
- 委 比 59.27%
- 總股本 7998.87万
- 歷史最高 14.87
- 量 比 0.55
- 振 幅 5.80%
- 歷史最低 8.50
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Raymond James Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $24
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $24.
01-09 22:09
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
Morgan Stanley Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $20
Morgan Stanley analyst Sean Laaman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $20.
2025-12-05 23:22
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
2025-11-25 22:08
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Oppenheimer analyst Matthew Biegler maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $23 to $22.
2025-11-14 02:08
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
BBO-10203, a first-in-class RAS:PI3Kα interaction breaker, selectively inhibits RAS-mediated PI3Kα-AKT signaling in tumors without causing hyperglycemia. Preclinical data show robust anti-tumor activity as monotherapy and in combination with BBOT's KRAS inhibitors, BBO-8520 and BBO-11818, across KRAS-mutant models. The drug is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ breast cancer, HR+/HER2- breast cancer...
2025-10-25 16:30
